CERA is led by a multi-disciplinary team with advanced expertise in genomics, bioethics, legal analysis, social science research, and related fields. The CERA leadership identifies priority areas in ELSI, ensures the integrity of our collection of ELSI resources and analysis, and guides the community building and engagement activities of the Center.
CERA Co-Investigators are affiliated with Stanford University, Columbia University, and The Hastings Center. They bring diverse expertise in online research portal development, meta-research, research synthesis methodologies, literature curation and annotation processes, ontology development, community engagement strategies, and public policy
Marnie Gelbart, Ph.D. leads initiatives for increasing awareness and conversation about the benefits and the ethical, legal, and social implications of genetic advances, in her role as Director of Programs at the Personal Genetics Education Project (pgEd) at Harvard University.
Maya Sabatello, LL.B., Ph.D. is Associate Professor of Clinical Bioethics at Columbia University. She specializes in bioethics, disability studies, and international/comparative human rights. Her research focuses on law, society, medicine, and disability; assisted reproductive technologies; and the ethical, legal, and social implications of genetics, especially in pediatrics and underserved populations.
David Magnus, Ph.D. is the Director of the Stanford Center for Biomedical Ethics, and Thomas A. Raffin Professor of Medicine and Biomedical Ethics, as well as Professor of Pediatrics. He is the Vice-Chair of the NIH Precision Medicine Initiative “All of Us Research Program” IRB and is Editor-in-Chief of the American Journal of Bioethics and of bioethics.net.
Teri Klein, Ph.D. is Professor in the Departments of Biomedical Data Sciences and Medicine / Division of Biomedical Informatics Research at Stanford University. She is Co-Principal Investigator of PharmGKB, a pharmacogenomics knowledge resource that annotates pharmacogenetic variants, curates drug dosing guidelines and FDA drug labels, summarizes important pharmacogenomics literature, and enables consortia, and, Co-Principal Investigator of CPIC, a pharmacogenetics consortium for the creation, curation and dissemination of peer-reviewed, evidence-based pharmacogenetics clinical practice guidelines.
Josephine Johnston, L.L.B, M.B.H.L is Director of Research and a Research Scholar at the Hastings Center. Trained in law and bioethics, Ms. Johnston has led several projects on ELSI issues related to prenatal genetic testing, gene editing, and newborn sequencing. She is an expert on the ethical, legal, and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
Steven Goodman, M.D., M.H.S., Ph.D. is Associate Dean of Clinical and Translational Research and Professor of Epidemiology & Population Health and Medicine, directing Stanford's CTSA training programs in medical research methods. He is co-director of the Meta-Research Innovation Center at Stanford (METRICS), and directs SPOR3, the Stanford Program on Research Rigor and Reproducibility.